Entod Pharmaceuticals has introduced Colladerm, the first AI bio-engineered collagen transdermal gel serum, in the 54 th National Conference of Indian Association of Dermatologists
.png "Sanofi Scales Up Hyderabad GCC with Big Investment")
Sanofi Healthcare India has expanded its Hyderabad Global Capability Centre, increasing capacity to 4,500 employees. Backed by a multi-hundred-million-dollar investment, the move strengthens India’s role in Sanofi’s global operations.
.png "Mankind Pharma Completes Global Supply Chain Revamp")
Mankind Pharma has completed a multi-year transformation of its global supply chain and procurement operations, cutting stock-outs by 75% and strengthening medicine access across 25+ international markets with AI-powered planning tools.
Natco Pharma shares jumped nearly 11% after the company received CDSCO approval to manufacture and market generic Semaglutide Injection in India, boosting investor sentiment and driving heavy trading volumes.
.png "Zydus Lifesciences Gets USFDA Nod for Ammonium Lactate Cream")
Zydus Lifesciences has received USFDA approval for Ammonium Lactate Cream, 12%, a treatment for dry skin and ichthyosis vulgaris.
Biocon’s Q3 results show strong revenue and profit growth, led by Biosimilars and Generics. Strategic debt reduction and R&D investments position the company for robust FY27 performance.
.jpeg "Thermo Fisher & Datavant Partner to Enhance Clinical Research")
Thermo Fisher partners with Datavant to enhance clinical research by connecting real-world data (RWD) and speeding up evidence generation for biotech and pharma companies.
.png "Novo Nordisk to Broaden Wegovy Access With Vials")
Novo Nordisk is preparing to introduce Wegovy in vial format, expanding delivery options for its blockbuster weight-loss drug as competition intensifies in the fast-growing obesity treatment market.
.png "Eli Lilly Bets Big on Weight-Loss Pill Ahead of FDA")
Eli Lilly and Company has built a $1.5 billion inventory of its experimental weight-loss pill ahead of a key FDA decision. The move signals confidence in approval and a push to avoid supply shortages at launch.
Biological E Limited has received Phase II prequalification from the World Health Organization for its Novel Oral Polio Vaccine type 2, strengthening global supply and boosting efforts to control vaccine-derived polio outbreaks worldwide.
.jpg)
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")